PRIME

NCT00364013 📎

Regimen

Experimental
Panitumumab + FOLFOX4
Control
FOLFOX4 alone

Population

KRAS wild-type metastatic CRC, 1L, previously untreated; showed harm signal in KRAS-mutant patients.

Key finding

1L mCRC KRAS-exon-2-wt: mPFS 9.6 vs 8.0 mo (HR 0.80, 95% CI 0.66-0.97, p=0.02); KRAS-wt ORR 55% vs 48%; KRAS-exon-2-mut: mPFS 7.3 vs 8.8 mo (HR 1.29, p=0.02) — panitumumab WORSENED PFS in KRAS-mut; primary endpoint PFS met in KRAS-wt

Source: PMID 20921465

Timeline

    Guideline citations

    • NCCN Colon (p.58)
    • NCCN Rectal (p.75)